Ireland
--:--IST
Recruiting Observational

Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections

NCT07593547 · tracked via the Priya Life Science Spain tracker
Sponsor
Instituto de Investigación Sanitaria Gregorio Marañón
Phase
Observational
Started
2026-03-06
Last updated
2026-10-02

Condition(s) studied

Bloodstream InfectionPneumonia - BacterialS Maltophilia Infections

Study summary

The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is:

• Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections?

Researchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients * S. maltophilia infections * Different episodes if a new infection ocurred \> 30 days since the index episode Exclusion Criteria: * isolates obtained from patients outside of hospital admission * microbiological or clinical colonization * hospitalizations shorter than 72 hours since the time zero * patients who died in the first 72 hours since the time zero or who were in imminent risk of death * polymicrobial infections * receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours * absence of data outcomes

Primary outcome measure(s)

  • All-cause mortality — At 30 days
  • All-cause mortality — At 60 days

Trial sites (1)

FacilityCityRegionStatus
Microbiology and Infectious Disease Department, Hospital General Universitario Gregorio Marañón Madrid Madrid Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07593547 on ClinicalTrials.gov ↗ ← All trials in Spain